A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL

Part of paid clinical trials in Canton, Ohio.

Sponsor
GlaxoSmithKline
Study ID
NCT07607925
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Lymphoma, Non-Hodgkin

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • GSK5926371 — DRUG
    GSK5926371 will be administered at different dose levels.

Study Details

The goal of this clinical trial is to learn if drug GSK5926371 works to treat a form of B-cell cancer (a type of blood cancer) that has returned or failed to respond to prior therapies in adults. The study will primarily assess the drugs safety and tolerability in participants. Additionally, it seeks to determine the clinical efficacy and pharmacokinetic (PK) properties of GSK5926371.

Key Dates

Start date
Jun 12, 2026
Status verified
Jun 2026
Primary completion
Sep 24, 2029
Completion
Sep 24, 2029

Study Design

Enrollment
49 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: GSK5926371

Primary Outcome Measure

Number of participants with dose limiting toxicities (DLTs) [ Time Frame: Up to 28 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
GSK Investigational SiteCantonOhio44718
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Nashat Gabrail (PRINCIPAL_INVESTIGATOR)

Find similar trials in Canton, OH

By research site
GSK Investigational Site· Canton, OH

Related Studies